Word: cancers
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...cancer vaccine is not like the measles shot you get as a kid. Instead of inoculating a healthy person against a foreign body like a virus, cancer vaccines use parts of tumors to help the patients' immune systems recognize diseased cells. Follicular lymphoma, a generally slow-moving cancer of the immune system that affects roughly 5,000 Spaniards each year, presents an especially enticing target for vaccine researchers because its cells all carry a protein, called an idiotype, that distinguishes them from their healthy counterparts. Mixing the idiotype with other substances that trigger immunological responses, "the vaccine presents a tumor...
Follicular lymphoma cannot currently be cured, but with chemotherapy and other treatments, a patient can usually achieve remission. The cancer almost always returns, however, and each subsequent remission tends to be shorter than the previous one. In 2001, Bendandi began vaccine therapy on 25 patients who had achieved a second remission with chemotherapy. The vaccine did not have any effect on five of the subjects, but the other 20 who did respond received a total of 10 vaccinations over 26 months. "Partway through the study, one of my patients - a hairdresser - came to me and said, 'I know the treatment...
...whom Bendandi refers are the nine scientists on his team at work on customized cancer vaccines. A treatment that uses a patient's own tumor cells to provoke an immunological response, vaccines are one of the most promising developments in the fight against cancer, and a goal hotly pursued by researchers around the world. Bendandi and his colleagues at Spain's Center for Applied Medical Research and the University of Navarre Hospital have gone farther than most. In a five-year-long study - its results were described as "remarkable" by the Journal of the National Cancer Institute which published...
...patients. Now Bendandi, who worked with Kwak at the nih, has erected what he calls "the third pillar" of customized therapy by demonstrating that the vaccine produces not just molecular benefits, but clinical ones as well. In other words, the patients in his study lived cancer free for longer than expected...
...take on the work of producing a different vaccine for every patient. But with three Phase III clinical trials for idiotype vaccines under way in the U.S., and several other types of custom treatments in development (on March 29, an fda advisory committee found "substantial evidence" that a prostate cancer vaccine is effective, increasing the likelihood of its approval), hopes for cancer vaccines are running high...